- Home
- USEA vs CLRB Comparison
USEA vs CLRB Comparison
Compare USEA & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | CLRB |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 24.5M |
| IPO Year | 2022 | 2008 |
Fundamental Metrics
Financial Performance| Metric | USEA | CLRB |
|---|---|---|
| Price | $3.08 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 101.9K | 28.1K |
| Earning Date | 05-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $2.20 |
| 52 Week High | $3.16 | $6.52 |
Technical Indicators
Market Signals| Indicator | USEA | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 74.50 | 38.54 |
| Support Level | $2.48 | $2.33 |
| Resistance Level | N/A | $2.70 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 98.00 | 24.14 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.